Senior insider sale
TAYSHA GENE THERAPIES, INC. — senior position signals high conviction
$2.04M
423.95K shares
What this filing means
NAGENDRAN SUKUMAR plans to sell 423.95K shares of TAYSHA GENE THERAPIES, INC. valued at approximately $2.04M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 1/23/2026ACC: 0001665124-26-000006
Director
Since Sep 2020
423.95K
Shares to sell
$2.04M
Approx. market value
113.82K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months1
RSU Award
Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.
1/23/2026
113.82KTotal acquired113.82K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
1/23/2026 | RSU Award Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer. | 113.82K | — |
| Total | 113.82K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
200K
Market value
$942.7K
1/12/2026
—Completed
Units to sell
110.13K
Market value
$522.8K
11/28/2025
Planned — Approximate Date
NasdaqPlanned
Units to sell
113.82K
Market value
$579.4K
1/23/2026
Total
Units
423.95K
Value
$2.04M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
1/12/2026 | 200K | $942.7K | — | Completed |
11/28/2025 | 110.13K | $522.8K | — | Completed |
| Planned — Approximate Date | ||||
1/23/2026 | 113.82K | $579.4K | Nasdaq | Planned |
| Total | 423.95K | $2.04M | ||